| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Professional fees | 711,169 | 924,580 | ||
| General and administrative | 231,404 | 339,377 | ||
| Research and development | 271,145 | 238,700 | ||
| Share-based compensation | 639,586 | 390,195 | ||
| Total operating expenses | 1,853,304 | 1,892,852 | ||
| Net operating loss | -1,853,304 | -1,892,852 | ||
| Interest expense | 1,177,999 | 1,760,025 | ||
| Loss on conversion of debt | - | -331,546 | ||
| Change in fair value of warrant liability | -79,447 | 121,476 | ||
| Other income (expense) | 56,271 | 12,668 | ||
| Total other income (expense) | -1,042,281 | -2,200,379 | ||
| Net loss before income taxes | -2,895,585 | -4,093,231 | ||
| Income taxes | - | 0 | ||
| Net loss | -2,895,585 | -4,093,231 | ||
| Net loss per share basic (in dollars per share) | -0.05 | -0.12 | ||
| Net loss per share diluted (in dollars per share) | -0.05 | -0.12 | ||
| Weighted average common shares outstanding (in shares) | 59,416,539 | 33,952,418 | ||
| Weighted-average common shares outstanding, diluted | 59,416,539 | 33,952,418 | ||
Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. (KLTO)